News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
721,671 Results
Type
Article (40903)
Company Profile (267)
Press Release (680491)
Multimedia
Podcasts (81)
Webinars (17)
Section
Business (204665)
Career Advice (2023)
Deals (35533)
Drug Delivery (110)
Drug Development (81380)
Employer Resources (173)
FDA (16409)
Job Trends (14944)
News (346380)
Policy (32725)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2567)
Accelerated approval (32)
Adcomms (24)
Allergies (142)
Alliances (49575)
ALS (169)
Alzheimer's disease (1667)
Antibody-drug conjugate (ADC) (309)
Approvals (16678)
Artificial intelligence (514)
Autoimmune disease (153)
Automation (39)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (189)
Biotechnology (174)
Bladder cancer (157)
Brain cancer (56)
Breast cancer (638)
Cancer (4797)
Cardiovascular disease (398)
Career advice (1708)
Career pathing (36)
CAR-T (282)
CDC (44)
Celiac Disease (2)
Cell therapy (742)
Cervical cancer (36)
Clinical research (69556)
Collaboration (1698)
Company closure (4)
Compensation (1156)
Complete response letters (54)
COVID-19 (2710)
CRISPR (88)
C-suite (841)
Cystic fibrosis (143)
Data (6215)
Decentralized trials (2)
Denatured (25)
Depression (131)
Diabetes (500)
Diagnostics (6687)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (251)
Drug pricing (184)
Drug shortages (28)
Duchenne muscular dystrophy (231)
Earnings (90162)
Editorial (57)
Employer branding (21)
Employer resources (152)
Events (117269)
Executive appointments (971)
FDA (19518)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1465)
Gene editing (194)
Generative AI (43)
Gene therapy (594)
GLP-1 (966)
Government (4659)
Grass and pollen (6)
Guidances (383)
Healthcare (18872)
HIV (58)
Huntington's disease (44)
IgA nephropathy (83)
Immunology and inflammation (249)
Immuno-oncology (57)
Indications (110)
Infectious disease (2978)
Inflammatory bowel disease (187)
Inflation Reduction Act (14)
Influenza (116)
Intellectual property (248)
Interviews (315)
IPO (16643)
IRA (50)
Job creations (3642)
Job search strategy (1428)
JPM (57)
Kidney cancer (16)
Labor market (85)
Layoffs (546)
Leadership (31)
Legal (7949)
Liver cancer (91)
Longevity (14)
Lung cancer (646)
Lymphoma (375)
Machine learning (42)
Management (59)
Manufacturing (792)
MASH (163)
Medical device (13768)
Medtech (13821)
Mergers & acquisitions (19960)
Metabolic disorders (1266)
Multiple sclerosis (160)
NASH (16)
Neurodegenerative disease (314)
Neuropsychiatric disorders (88)
Neuroscience (2890)
Neurotech (1)
NextGen: Class of 2026 (6519)
Non-profit (4514)
Now hiring (67)
Obesity (594)
Opinion (257)
Ovarian cancer (166)
Pain (197)
Pancreatic cancer (226)
Parkinson's disease (279)
Partnered (33)
Patents (494)
Patient recruitment (488)
Peanut (56)
People (58863)
Pharmaceutical (62)
Pharmacy benefit managers (29)
Phase 1 (21683)
Phase 2 (30612)
Phase 3 (22806)
Pipeline (5265)
Policy (281)
Postmarket research (2564)
Preclinical (9196)
Press Release (64)
Prostate cancer (237)
Psychedelics (48)
Radiopharmaceuticals (279)
Rare diseases (831)
Real estate (5954)
Recruiting (70)
Regulatory (24475)
Reports (52)
Research institute (2387)
Resumes & cover letters (352)
Rett syndrome (27)
RNA editing (16)
RSV (77)
Schizophrenia (147)
Series A (238)
Series B (190)
Service/supplier (11)
Sickle cell disease (95)
Special edition (21)
Spinal muscular atrophy (157)
Sponsored (41)
Startups (3614)
State (2)
Stomach cancer (17)
Supply chain (104)
Tariffs (84)
The Weekly (54)
Vaccines (1002)
Venture capital (88)
Weight loss (380)
Women's health (91)
Worklife (18)
Date
Today (142)
Last 7 days (594)
Last 30 days (2104)
Last 365 days (29899)
2026 (3399)
2025 (30172)
2024 (35215)
2023 (40075)
2022 (51175)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (736)
Alabama (83)
Alaska (7)
Arizona (309)
Arkansas (13)
Asia (39220)
Australia (6409)
California (11279)
Canada (3282)
China (1099)
Colorado (477)
Connecticut (475)
Delaware (336)
Europe (84507)
Florida (1686)
Georgia (355)
Hawaii (3)
Idaho (61)
Illinois (859)
India (65)
Indiana (519)
Iowa (22)
Japan (429)
Kansas (126)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1380)
Massachusetts (8076)
Michigan (324)
Minnesota (628)
Mississippi (5)
Missouri (128)
Montana (32)
Nebraska (28)
Nevada (122)
New Hampshire (78)
New Jersey (2997)
New Mexico (28)
New York (2972)
North Carolina (1447)
North Dakota (8)
Northern California (5512)
Ohio (332)
Oklahoma (21)
Oregon (41)
Pennsylvania (2275)
Puerto Rico (24)
Rhode Island (47)
South America (1108)
South Carolina (66)
South Dakota (1)
Southern California (4388)
Tennessee (174)
Texas (1738)
United States (39960)
Utah (334)
Vermont (1)
Virginia (260)
Washington D.C. (81)
Washington State (918)
West Virginia (4)
Wisconsin (108)
Wyoming (2)
721,671 Results for "anaptysbio inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Legal
UPDATE: GSK’s Tesaro Sues AnaptysBio Over Current Jemperli Contract; Anaptys Countersues
After GSK subsidiary Tesaro filed a lawsuit Thursday claiming that AnaptysBio breached “certain requirements” under their 2014 license agreement involving GSK’s Jemperli, Anaptys responded Friday morning.
November 21, 2025
·
3 min read
·
Tristan Manalac
Cancer
AnaptysBio Plans Business Split To Sharpen Focus on Asset Value
The business separation, expected to be completed by the end of 2026, will result in two new companies, one focused on biopharma operations and the other on royalty management.
October 1, 2025
·
2 min read
·
Tristan Manalac
IN PARTNERSHIP WITH ANAPTYSBIO
Beyond the Gluten-Free Diet: A New Era in Celiac Disease Treatment
In this episode of Denatured presented by AnaptysBio, Jennifer Smith-Parker speaks to Dr. Joe Murray, Mayo Clinic; Marilyn Geller, the Celiac Disease Foundation; and Dr. Paul Lizzul, AnaptysBio, about the challenges and opportunities facing celiac disease treatment.
December 11, 2025
·
1 min read
·
Jennifer Smith-Parker
Business
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it has appointed John Orwin chairman of the AnaptysBio Board of Directors.
September 18, 2023
·
5 min read
Biotech Beach
AnaptysBio Announces Participation in Upcoming June 2023 Investor Conferences
AnaptysBio, Inc. announced that Daniel Faga, interim president and chief executive officer of AnaptysBio, and other members of its senior management team are scheduled to participate in both of the upcoming investor conferences below:
May 30, 2023
·
3 min read
Biotech Beach
AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, and Dr. Paul Lizzul, chief medical officer, will present at the Stifel 2023 Immunology and Inflammation Virtual Summit later this month.
September 12, 2023
·
3 min read
Business
AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the second quarter ended June 30, 2023 and provided a business update.
August 7, 2023
·
11 min read
Drug Development
AnaptysBio Touts Positive Top-Line Phase III Data for Pustular Psoriasis Candidate
The company’s experimental lgG4 antibody met the primary endpoint in a late-stage study of the rare skin disease. AnaptysBio will submit an application to the FDA by the third quarter of 2024.
October 16, 2023
·
2 min read
·
Matt Olszewski
Business
AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors
AnaptysBio, Inc., a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced the appointment of Rita Jain, M.D., to the company’s Board of Directors, effective immediately.
April 6, 2023
·
5 min read
Business
AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the first quarter ended March 31, 2023 and provided pipeline updates.
May 11, 2023
·
10 min read
1 of 72,168
Next
